Westfield, NJ, United States of America

Brian DerHua Lu

This inventor holds 1 USPTO granted patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brian DerHua Lu. Retrieved from https://idiyas.com/inventor/brian-derhua-lu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Brian DerHua Lu: Innovating Cancer Treatment Evaluation

Introduction

Brian DerHua Lu is a notable inventor based in Westfield, New Jersey. His innovative work has contributed significantly to the field of cancer treatment evaluation, focusing on Ewing's sarcoma, a rare type of cancer.

Latest Patents

Brian holds a patent for his invention titled "FDG-PET evaluation of Ewing's sarcoma sensitivity." This patent encompasses methods designed to evaluate the efficacy of an IGF1R inhibitor, such as an anti-IGF1R antibody, specifically for treating Ewing's sarcoma tumors. The methodology involves determining tumoral glucose metabolism at an early stage in the treatment process using techniques like FDG-PET/CT scans.

Career Highlights

Brian DerHua Lu is affiliated with Merck Sharp & Dohme Corporation, a well-known entity in the pharmaceutical industry. His role in developing innovative evaluation methods reflects his commitment to advancing cancer treatment methodologies and improving patient outcomes.

Collaborations

Throughout his career, Brian has collaborated with distinguished colleagues such as Siu-Long Yao and Cynthia Seidel-Dugan. These collaborations have fostered an environment of innovation and have been crucial in driving forward the research and development efforts pertinent to his patent.

Conclusion

In summary, Brian DerHua Lu stands out as a significant inventor in the realm of cancer treatment evaluation. His contributions through patents mark a pivotal advancement in understanding and improving therapies for Ewing's sarcoma, signifying a hopeful future for those affected by this challenging condition.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…